Authors:
MAST AE
BLINDER MA
GRONOWSKI AM
CHUMLEY C
SCOTT MG
Citation: Ae. Mast et al., CLINICAL UTILITY OF THE SOLUBLE TRANSFERRIN RECEPTOR AND COMPARISON WITH SERUM FERRITIN IN SEVERAL POPULATIONS, Clinical chemistry, 44(1), 1998, pp. 45-51
Authors:
MAST AE
HIGUCHI DA
HUANG ZF
WARSHAWSKY I
SCHWARTZ AL
BROZE GJ
Citation: Ae. Mast et al., GLYPICAN-5 IS A BINDING-PROTEIN ON THE HEPG2 CELL-SURFACE FOR TISSUE FACTOR PATHWAY INHIBITOR, Biochemical journal, 327, 1997, pp. 577-583
Authors:
MAST AE
HUANG ZF
WARSHAWSKY I
SCHWARTZ AL
BROZE GJ
Citation: Ae. Mast et al., GLYPICAN-3 IS A TISSUE FACTOR PATHWAY INHIBITOR BINDING-PROTEIN ON THE HEPG2 CELL-SURFACE, Blood, 88(10), 1996, pp. 1866-1866
Citation: Ae. Mast et Gj. Broze, PHYSIOLOGICAL CONCENTRATIONS OF TISSUE FACTOR PATHWAY INHIBITOR DO NOT INHIBIT PROTHROMBINASE, Blood, 87(5), 1996, pp. 1845-1850
Authors:
DENGLER R
LOTTSPEICH F
OBERTHUR W
MAST AE
EMMERICH B
Citation: R. Dengler et al., LIMITED PROTEOLYSIS OF ALPHA(1)-PROTEINASE INHIBITOR (ALPHA(1)-PL) INACUTE-LEUKEMIA - STUDIES ON THE RESULTING FRAGMENTS AND IMPLICATION FOR THE STRUCTURE OF THE INACTIVATED INHIBITOR, Biological chemistry Hoppe-Seyler, 376(3), 1995, pp. 165-172
Authors:
MAST AE
BLINDER MA
GRONOWSKI A
CHUMLEY C
SCOTT MG
Citation: Ae. Mast et al., THE CLINICAL UTILITY OF THE SERUM TRANSFERRIN RECEPTOR LEVEL IN THE EVALUATION OF IRON-DEFICIENCY ANEMIA, Blood, 86(10), 1995, pp. 498-498